You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

  • Technology appraisal guidance
  • Reference number: TA171
  • Published:  18 June 2009
  • Last updated:  26 June 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Appendix A: GE Decision paper

Appendix A: GE Decision paper Appendix A: GE Decision paper
13 November 2010
(74.29 Kb 21 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 12 November 2012

Back to top